A poster by Biocytogen
Yanan Guo, Yanan Li, Xiaofei Zhou, Youhong Su, Qingcong Lin., Biocytogen
In recent years, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
Tumor necrosis factor receptor 2(TNFR2), also known as tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), is a transmembrane receptor that plays an essential role in immune modulation and tissue regeneration (Chen et al., 2008).
TNFR2 is mainly expressed on immune cells specifically on the surface of potent regulatory T cells (Tregs) (Wu et al., 2008) and promote the proliferation of Tregs through nuclear factor kappa B (NF-κB) (Chen et al., 2013; Rodríguez et al., 2011).
Anti-TNFR2 antibodies have been developed to inhibit NF-κB driven growth and have revived excitement for the use of anti-TNFR2 antibodies in the clinic.
To investigate the role of TNFR2, Biocytogen generated TNFR2 humanized mouse for both in vitro function validation of signaling pathway and in vivo efficacy evaluation of TNFR2 antibodies.
In this model, the exons 2~6 of mouse Tnfrsf1b gene which encode the extracellular domain were replaced by human TNFRSF1B counterparts.
Human TNFR2 was detectable on the Tregs in spleen and the TNFR2 antibodies associated well to the splenocytes of the TNFR2 humanized mice.
Basal leukocyte subpopulations of TNFR2 humanized mice were comparable to those of wild-type mice, including T/B cells, NK cells, DC, granulocytes and monocytes/macrophages.
Anti-human TNFR2 antibodies bound well with CD3+ T cells and inhibited tumor growth in TNFR2humanized mice.
Taken together, TNFR2 humanized mice is a useful tool for in vivo efficacy evaluation of therapeutics that target human.
Find out more at biocytogen.com or renmab.com.
